dihexa retracted paper controversy Alzheimer's scientist forced to retract during his own replication effort Dynamics of cross-platform attention to

To 150:1

The most significant data comes from the REDEFINE trials, evaluating the co-administration of Cagrilintide and Semaglutide These findings highlight the synergistic potential of combining the amylin pathway (Cagrilintide) and the GLP-1 pathway (Semaglutide) to achieve superior metabolic and weight loss outcomes compared to either agent alone

Most trials run for a few years in higher-risk patients, not decades in low-risk ones, so their reassurance does not automatically extend to 30+ years of treatment in a younger, healthier population

This tends to begin after 2-3 months of your rapid weight loss

high levels of MMA can indicate a vitamin deficiency